diabetic angiopathies

Summary

Summary: VASCULAR DISEASES that are associated with DIABETES MELLITUS.

Top Publications

  1. ncbi Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial
    Eric S Kilpatrick
    Department of Clinical Biochemistry, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, UK
    Diabetes Care 30:707-12. 2007
  2. ncbi Biochemistry and molecular cell biology of diabetic complications
    M Brownlee
    Department of Medicine, Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York, 10461, USA
    Nature 414:813-20. 2001
  3. doi Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    Anushka Patel
    N Engl J Med 358:2560-72. 2008
  4. pmc Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
    I M Stratton
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE
    BMJ 321:405-12. 2000
  5. ncbi 10-year follow-up of intensive glucose control in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1577-89. 2008
  6. ncbi Diabetes and atherosclerosis: epidemiology, pathophysiology, and management
    Joshua A Beckman
    Leducq Center for Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    JAMA 287:2570-81. 2002
  7. ncbi Advanced glycation end products: sparking the development of diabetic vascular injury
    Alison Goldin
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Circulation 114:597-605. 2006
  8. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
  9. pmc Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
    Rachel Huxley
    George Institute for International Health, University of Sydney, PO Box M201, Sydney, NSW 2050, Australia
    BMJ 332:73-8. 2006
  10. pmc Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010

Detail Information

Publications287 found, 100 shown here

  1. ncbi Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial
    Eric S Kilpatrick
    Department of Clinical Biochemistry, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, UK
    Diabetes Care 30:707-12. 2007
    ..This study has examined whether these also were predictors of micro- and macrovascular complications in type 1 diabetic patients participating in the Diabetes Control and Complications Trial (DCCT)...
  2. ncbi Biochemistry and molecular cell biology of diabetic complications
    M Brownlee
    Department of Medicine, Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York, 10461, USA
    Nature 414:813-20. 2001
    ..This integrating paradigm provides a new conceptual framework for future research and drug discovery...
  3. doi Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    Anushka Patel
    N Engl J Med 358:2560-72. 2008
    ..In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain...
  4. pmc Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
    I M Stratton
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE
    BMJ 321:405-12. 2000
    ..To determine the relation between exposure to glycaemia over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes...
  5. ncbi 10-year follow-up of intensive glucose control in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1577-89. 2008
    ..We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes...
  6. ncbi Diabetes and atherosclerosis: epidemiology, pathophysiology, and management
    Joshua A Beckman
    Leducq Center for Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    JAMA 287:2570-81. 2002
    ..Complications of atherosclerosis cause most morbidity and mortality in patients with diabetes mellitus. Despite the frequency and severity of disease, proven medical therapy remains incompletely understood and underused...
  7. ncbi Advanced glycation end products: sparking the development of diabetic vascular injury
    Alison Goldin
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Circulation 114:597-605. 2006
    ..Because of the emerging evidence about the adverse effects of AGEs on the vasculature of patients with diabetes, a number of different therapies to inhibit AGEs are under investigation...
  8. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
    ..The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain...
  9. pmc Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
    Rachel Huxley
    George Institute for International Health, University of Sydney, PO Box M201, Sydney, NSW 2050, Australia
    BMJ 332:73-8. 2006
    ..To estimate the relative risk for fatal coronary heart disease associated with diabetes in men and women...
  10. pmc Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
    ..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
  11. ncbi Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes
    Cindy J M Loomans
    Department of Vascular Medicine and Diabetology, University Medical Center Utrecht, Utrecht, The Netherlands
    Diabetes 53:195-9. 2004
    ..We hypothesize that EPC dysfunction contributes to the pathogenesis of vascular complications in type 1 diabetes...
  12. ncbi Intensive glucose control and macrovascular outcomes in type 2 diabetes
    F M Turnbull
    The George Institute for International Health, University of Sydney, Sydney, NSW 2050, Australia
    Diabetologia 52:2288-98. 2009
    ..The aim of these analyses was to generate more precise estimates of the effects of more-intensive, compared with less-intensive, glucose control on the risk of major cardiovascular events amongst patients with type 2 diabetes...
  13. ncbi Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes
    N J Morrish
    North Bedfordshire Diabetes Centre, Bedford Hospital, UK
    Diabetologia 44:S14-21. 2001
    ..The low excess mortality in the Japanese cohort could have implications for the possible reduction of the burden of mortality associated with diabetes in other parts of the world...
  14. ncbi Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
    S P Laing
    Section of Epidemiology, Brookes Lawley Building, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Diabetologia 46:760-5. 2003
    ..The Diabetes UK cohort, essentially one of patients with Type 1 diabetes, now has sufficient follow-up to report all heart disease, and specifically ischaemic heart disease, mortality rates by age...
  15. ncbi Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
    Thomas Nystrom
    Dept of Internal Medicine, Stockholm South Hospital, Karolinska Institute, Stockholm SE 118 83, Sweden
    Am J Physiol Endocrinol Metab 287:E1209-15. 2004
    ..This beneficial vascular effect of GLP-1 adds yet another salutary property of the peptide useful in diabetes treatment...
  16. ncbi NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
    Charles M Alexander
    Outcomes Research and Management, U S Medical and Scientific Affairs, Merck and Co, Inc, West Point, PA, USA
    Diabetes 52:1210-4. 2003
    ..However, individuals with diabetes without metabolic syndrome had no greater prevalence of CHD compared with those with neither...
  17. ncbi Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I
    Mark A Creager
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:1527-32. 2003
  18. ncbi Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    Lars Ryden
    Department of Cardiology, Karolinska University Hospital, Sweden
    Eur Heart J 28:88-136. 2007
  19. ncbi Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus
    Gian Paolo Fadini
    Department of Clinical and Experimental Medicine, Division of Metabolic Diseases, University of Padova, School of Medicine, Padova, Italy
    J Am Coll Cardiol 45:1449-57. 2005
    ..We sought to establish whether a reduction in endothelial progenitor cells (EPCs) has a putative role in peripheral vascular disease (PVD) of type 2 diabetic patients...
  20. ncbi Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
    M Hanefeld
    Centre for Clinical Studies, GWT, Technical University of Dresden, Fiedlerstrasse 34, 01307 Dresden, Germany
    Eur Heart J 25:10-6. 2004
    ..To assess if treatment with the alpha-glucosidase inhibitor acarbose can reduce cardiovascular events in type 2 diabetic patients...
  21. pmc Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes
    Aino Soro-Paavonen
    Albert Einstein Juvenile Diabetes Research Foundation Centre for Diabetes Complications, Diabetes Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
    Diabetes 57:2461-9. 2008
    ..This study examines the effects of deletion of RAGE on the development of atherosclerosis in the diabetic apoE(-/-) model of accelerated atherosclerosis...
  22. ncbi Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
    L Park
    Department of Surgery, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Nat Med 4:1025-31. 1998
    ....
  23. pmc Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells
    Xueliang Du
    Diabetes Research Center, Albert Einstein College of Medicine, Bronx, New York, USA
    J Clin Invest 112:1049-57. 2003
    ..Elevated glucose increased poly(ADP-ribosyl)ation of GAPDH in WT aortae, but not in the aortae from PARP-1-deficient mice. Thus, inhibition of PARP blocks hyperglycemia-induced activation of multiple pathways of vascular damage...
  24. ncbi Coronary microvascular dysfunction
    Paolo G Camici
    Medical Research Council Clinical Sciences Centre Hammersmith Hospital, and National Heart and Lung Institute, Imperial College, London, United Kingdom
    N Engl J Med 356:830-40. 2007
  25. ncbi Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes
    Sridevi Devaraj
    Laboratory for Atherosclerosis and Metabolic Research, Department of Pathology, UC Davis Medical Center, Sacramento, CA 95817, USA
    Diabetes 55:774-9. 2006
    ..These results have a major implication on our understanding of the role of inflammation in vasculopathies in type 1 diabetes...
  26. ncbi Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
    L Blonde
    Ochsner Clinic Foundation, New Orleans, LA, USA
    Diabetes Obes Metab 8:436-47. 2006
    ..This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET)...
  27. ncbi Mortality trends in men and women with diabetes, 1971 to 2000
    Edward W Gregg
    National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30341 3727, USA
    Ann Intern Med 147:149-55. 2007
    ..Whether mortality rates among diabetic adults or excess mortality associated with diabetes in the United States has declined in recent decades is not known...
  28. ncbi Skin autofluorescence is a strong predictor of cardiac mortality in diabetes
    Robbert Meerwaldt
    Department of Medicine, University Medical Center Groningen, Groningen, Netherlands
    Diabetes Care 30:107-12. 2007
    ..The aim of the present study was to evaluate the relationship between skin autofluorescence and metabolic burden (hyperglycemia and hyperlipidemia) and its relationship with CHD and mortality...
  29. pmc Determinants of vascular function in patients with type 2 diabetes
    Katerina K Naka
    Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece
    Cardiovasc Diabetol 11:127. 2012
    ..The aim of our study was to investigate the predictors of vascular dysfunction in T2DM patients...
  30. ncbi Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications
    Sonali Jindal
    Department of Pathology, Hindu Rao Hospital, Delhi, India
    Hematology 16:86-9. 2011
    ..This study was aimed at evaluating platelet indices in diabetic versus non-diabetic patients and assessing their utility as indicators of presence of complications in patients with DM...
  31. ncbi Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase
    Garry X Shen
    Department of Internal Medicine, University of Manitoba, 835 715 McDermot Avenue, Winnipeg MB R3E 3P4, Canada
    Can J Physiol Pharmacol 88:241-8. 2010
    ....
  32. pmc Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial
    Lawrence H Young
    Yale University School of Medicine, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, CT 06520, USA
    JAMA 301:1547-55. 2009
    ..Coronary artery disease (CAD) is the major cause of mortality and morbidity in patients with type 2 diabetes. But the utility of screening patients with type 2 diabetes for asymptomatic CAD is controversial...
  33. ncbi Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
    R M Conroy
    Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
    Eur Heart J 24:987-1003. 2003
    ..The SCORE project was initiated to develop a risk scoring system for use in the clinical management of cardiovascular risk in European clinical practice...
  34. ncbi Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes
    C G Egan
    Department of Neuroscience, University of Siena, Via A Moro, 53100, Siena, Italy
    Diabetologia 51:1296-305. 2008
    ..Since expression of chemokine (C-X-C motif) receptor 4 (CXCR4) has been associated with mobilisation and recruitment of progenitor cells, CXCR4 expression was also analysed...
  35. ncbi Diabetes and advanced glycation endproducts
    H Vlassara
    Department of Geriatrics, Mount Sinai School of Medicine, NY 10029, USA
    J Intern Med 251:87-101. 2002
    ..The final disposal of AGE depends on renal clearance. Promising pharmacologic strategies to prevent AGE formation, reduce AGE toxicity, and/or inactivate AGE are under investigation...
  36. ncbi Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study
    M T Schram
    Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
    Diabetologia 48:370-8. 2005
    ..The pathogenesis of vascular complications in type 1 diabetes is poorly understood, but may involve chronic, low-grade inflammation. We investigated the association of markers of inflammation with vascular complications in type 1 diabetes...
  37. ncbi Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications
    J Frystyk
    Medical Research Laboratories, Clinical Institute and Medical Department M Diabetes and Endocrinology, Aarhus University Hospital, Aarhus C, Denmark
    Diabetologia 48:1911-8. 2005
    ..In type 1 diabetic patients, the relationship between ADPN and the presence of vascular complications is largely unknown...
  38. ncbi Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease
    C D A Stehouwer
    Department of Internal Medicine, University Hospital Maastricht, P Debyelaan 25, P O Box 5800, 6202 AZ Maastricht, The Netherlands
    Diabetologia 51:527-39. 2008
    ..New pharmacological strategies to reduce arterial stiffness are likely to be especially relevant to individuals with diabetes...
  39. pmc Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes
    Jin Young Shin
    Department of Family Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
    Cardiovasc Diabetol 10:30. 2011
    ..The purpose of this study is to investigate the relationship between FPG and arterial stiffness in non-diabetic healthy subjects...
  40. ncbi Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications
    F Chiarelli
    Department of Medicine, University of Chieti, Italy
    Diabet Med 17:650-6. 2000
    ....
  41. ncbi Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus
    Adriaan Kooy
    Department of Internal Medicine and Bethesda Diabetes Research Center, RA Hoogeveen, The Netherlands
    Arch Intern Med 169:616-25. 2009
    ..We investigated whether metformin hydrochloride has sustained beneficial metabolic and (cardio) vascular effects in patients with type 2 diabetes mellitus (DM2)...
  42. pmc Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications
    Sridevi Devaraj
    Department of Pathology, Laboratory for Atherosclerosis and Metabolic Research, UCDavis Medical Center, Sacramento, CA 95817, USA
    Diabetes 56:2790-6. 2007
    ....
  43. ncbi Prognostic value of coronary artery calcium screening in subjects with and without diabetes
    Paolo Raggi
    Section of Cardiology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    J Am Coll Cardiol 43:1663-9. 2004
    ..The study was done to determine the interaction of coronary artery calcium and diabetes mellitus for prediction of all-cause death...
  44. pmc Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy
    Helen Vlassara
    Division of Experimental Diabetes and Aging, Department of Geriatrics, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 99:15596-601. 2002
    ..05). Thus in diabetes, environmental (dietary) AGEs promote inflammatory mediators, leading to tissue injury. Restriction of dietary AGEs suppresses these effects...
  45. pmc Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
    Dean T Eurich
    Institute of Health Economics, Edmonton, AB, Canada, T5J 3N4
    BMJ 335:497. 2007
    ..To review the literature on the association between antidiabetic agents and morbidity and mortality in people with heart failure and diabetes...
  46. pmc Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study
    Johanna W Nin
    Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands
    Diabetes Care 34:442-7. 2011
    ....
  47. ncbi Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice
    Paul Lewis
    Oxidative Stress Group, JDRF Diabetes and Metabolism Division, Baker Heart Research Institute, PO Box 6492, St Kilda Rd Central, Melbourne, VIC 8008, Australia
    Circulation 115:2178-87. 2007
    ..We induced diabetes in mice deficient for both GPx1 and apolipoprotein E (ApoE) to determine whether this is merely an association or whether GPx1 has a direct effect on diabetes-associated atherosclerosis...
  48. ncbi Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy
    N Zhang
    Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou China
    Exp Clin Endocrinol Diabetes 116:104-11. 2008
    ..These results show that MSCs transplantation improved cardiac function in the rat DCM model, possibly through angiogenesis and attenuation of cardiac remodeling...
  49. pmc Endothelial dysfunction as a potential contributor in diabetic nephropathy
    Takahiko Nakagawa
    Division of Renal Disease and Hypertension, University of Colorado Denver, 12700 East 19th Avenue, Aurora, CO 80045, USA
    Nat Rev Nephrol 7:36-44. 2011
    ..If endothelial dysfunction is the key factor required for diabetic nephropathy, then agents that improve endothelial function or raise intraglomerular nitric oxide level could be beneficial in the treatment of diabetic nephropathy...
  50. ncbi Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study
    Frans J Th Wackers
    Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Diabetes Care 27:1954-61. 2004
    ..To assess the prevalence and clinical predictors of silent myocardial ischemia in asymptomatic patients with type 2 diabetes and to test the effectiveness of current American Diabetes Association screening guidelines...
  51. ncbi Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes
    K Tanaka
    Department of Nephrology, Hypertension, Diabetology, Endocrinology and Metabolism, Fukushima, Japan
    Diabet Med 29:492-500. 2012
    ..The aim of this study was to evaluate associations between skin autofluorescence and vascular complications in non-Caucasian patients with Type 2 diabetes...
  52. ncbi Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
    Elizabeth Selvin
    Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
    Ann Intern Med 141:421-31. 2004
    ..In persons with diabetes, chronic hyperglycemia (assessed by glycosylated hemoglobin level) is related to the development of microvascular disease; however, the relation of glycosylated hemoglobin to macrovascular disease is less clear...
  53. ncbi Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex
    Klemens Raile
    Department of Pediatric Endocrinology and Diabetes, Charite Children s Hospital, Augustenburger Platz 1, 13353 Berlin, Germany
    Diabetes Care 30:2523-8. 2007
    ..To give an up-to-date profile of nephropathy and the involvement of risk factors in a large, prospective cohort of patients with type 1 diabetes and largely pediatric and adolescent onset of disease...
  54. pmc TCF7L2 single nucleotide polymorphisms, cardiovascular disease and all-cause mortality: the Atherosclerosis Risk in Communities (ARIC) study
    S J Bielinski
    Division of Epidemiology and Community Health, University of Minnesota, 1300 South 2nd Street, Suite 300, Minneapolis, MN 55454, USA
    Diabetologia 51:968-70. 2008
    ..We hypothesised that TCF7L2 single nucleotide polymorphisms (SNPs) are associated with cardiovascular disease (CVD) and that the associations differ in diabetic and non-diabetic persons...
  55. ncbi Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25)
    H Yokoyama
    Jiyugaoka Medical Clinic, Internal Medicine, West 6, South 6 4 3, Obihiro 080 0016, Japan
    Diabetologia 55:1911-8. 2012
    ..Clarification of this relationship is important for clinical decision-making for both low- and high-risk diabetic patients...
  56. ncbi Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited
    Stephen W Schaffer
    University of South Alabama, Department of Pharmacology, Mobile, AL 36688, USA
    Vascul Pharmacol 57:139-49. 2012
    ..The present review critiques the major premises of the hypothesis and concludes that further study of the role of oxidative stress in the development of diabetes-mediated vasculature dysfunction is warranted...
  57. ncbi HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2
    A Sugawara
    Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, 3 2 7 Miya machi, Mito, Ibaraki, Japan, 310 0015
    Diabetologia 55:2128-31. 2012
    ..4 mg/mmol (≥ 30 mg/g) in at least two of three consecutive urine samples in Japanese patients with type 2 diabetes...
  58. pmc Peroxynitrite mediates diabetes-induced endothelial dysfunction: possible role of Rho kinase activation
    Azza B el-Remessy
    College of Pharmacy, The University of Georgia, 1120 15th Street, HM 1200, Augusta, GA 30912, USA
    Exp Diabetes Res 2010:247861. 2010
    ..Together, peroxynitrite can suppress eNOS expression via activation of RhoA and hence cause vascular dysfunction...
  59. ncbi The rise and fall of HbA(1c) as a risk marker for diabetes complications
    E S Kilpatrick
    Department of Clinical Biochemistry, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK
    Diabetologia 55:2089-91. 2012
    ....
  60. ncbi Involvement of microparticles in diabetic vascular complications
    Gala Tsimerman
    Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Thromb Haemost 106:310-21. 2011
    ..This study demonstrates that MP characteristics are related to the specific type of vascular complications and may serve as a bio-marker for the pro- coagulant state and vascular pathology in patients with T2DM...
  61. ncbi Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence
    E Bonora
    Division of Endocrinology and Metabolic Disease, University of Verona Medical School, Ospedale Maggiore, Piazzale Stefani 1, Verona, Italy
    Diabetologia 44:2107-14. 2001
    ..Trials specifically designed to address this issue are needed to determine whether postprandial hyperglycaemia plays an independent and causative role in cardiovascular disease in patients with Type II diabetes...
  62. pmc Cerebral perfusion and aortic stiffness are independent predictors of white matter brain atrophy in type 1 diabetic patients assessed with magnetic resonance imaging
    Saskia G C van Elderen
    Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
    Diabetes Care 34:459-63. 2011
    ..To identify vascular mechanisms of brain atrophy in type 1 diabetes mellitus (DM) patients by investigating the relationship between brain volumes and cerebral perfusion and aortic stiffness using magnetic resonance imaging (MRI)...
  63. ncbi Type 2 diabetes is associated with increased pulse wave velocity measured at different sites of the arterial system but not augmentation index in a Chinese population
    Minghua Zhang
    Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China
    Clin Cardiol 34:622-7. 2011
    ..Moreover, the association between pulse wave velocity (PWV) and augmentation index (AIx) in diabetes is poorly understood...
  64. ncbi Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease
    Caterina Marciano
    Department of Clinical Medicine, Cardiovascular and Immunological Sciences, University Federico II, Napoli, Italy
    Eur J Nucl Med Mol Imaging 39:1199-206. 2012
    ..We assessed the impact of type 2 diabetes, in the presence of other major cardiovascular risk factors, on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease (CAD)...
  65. pmc The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
    Peter P Toth
    CGH Medical Center, 101 East Miller Rd, Sterling, IL, 61081, USA
    Cardiovasc Diabetol 11:109. 2012
    ....
  66. pmc Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice
    De xiu Bu
    Division of Surgical Science, Department of Surgery, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Circ Res 106:1040-51. 2010
    ..The multiligand RAGE (receptor for advanced glycation end products) contributes to atherosclerosis in apolipoprotein (Apo)E-null mice...
  67. ncbi Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises
    Frankie B Stentz
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    Diabetes 53:2079-86. 2004
    ..Return of these values to normal levels with insulin therapy demonstrates a robust anti-inflammatory effect of insulin...
  68. ncbi Tissue Doppler echocardiography in persons with hypertension, diabetes, or ischaemic heart disease: the Copenhagen City Heart Study
    Rasmus Mogelvang
    Copenhagen City Heart Study, Epidemiological Research Unit, Bispebjerg Hospital, Copenhagen, Denmark
    Eur Heart J 30:731-9. 2009
    ..To test the hypothesis that echocardiographic tissue Doppler imaging (TDI) reveals reduced myocardial function in hypertension, diabetes, and ischaemic heart disease (IHD) in the general population...
  69. ncbi Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes
    Gian Paolo Fadini
    Department of Clinical and Experimental Medicine, Metabolic Division, University of Padova, Medical School, Padova, Italy
    Circ Res 108:1112-21. 2011
    ..Acquisition of a procalcific phenotype by resident or circulating cells is important for calcification of atherosclerotic plaques, which is common in diabetes...
  70. ncbi Peripheral arterial disease in patients with diabetes
    Steven P Marso
    Mid America Heart Institute, University of Missouri Kansas City, Saint Luke s Hospital, Kansas City, Missouri 64111, USA
    J Am Coll Cardiol 47:921-9. 2006
    ..This article will review the clinical implications of the consensus statement and highlight the treatment options available in order to help prevent future ischemic events in diabetic individuals with PAD...
  71. ncbi Vascular complications in diabetes mellitus: the role of endothelial dysfunction
    Casper G Schalkwijk
    Department of Internal Medicine, Academic Hospital Maastricht, The Netherlands
    Clin Sci (Lond) 109:143-59. 2005
    ..Finally, the components of the metabolic syndrome can impair endothelial function...
  72. pmc Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice
    G C Schatteman
    Anatomy and Cell Biology, University of Iowa, Iowa City, Iowa 52245, USA
    J Clin Invest 106:571-8. 2000
    ..Our findings suggest that CD34(+) cells may be a useful tool for therapeutic angiogenesis in diabetics...
  73. ncbi Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes
    Gang Hu
    Diabetes and Genetic Epidemiology Unit, Department of Epidemiology and Health Promotion, National Public Health Institute, Mannerheimintie 166, FIN 00300 Helsinki, Finland
    Diabetes Care 28:799-805. 2005
    ..The aim of this study was to examine both single and joint associations of physical activity and conventional cardiovascular risk factors with total and cardiovascular mortality among patients with diabetes...
  74. ncbi Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus
    H L Lutgers
    Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands
    Diabetologia 52:789-97. 2009
    ..We investigated the prognostic value of skin autofluorescence for cardiovascular events in combination with the UKPDS risk engine in a cohort of patients with type 2 diabetes managed in primary care...
  75. ncbi Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study
    Robert S Elkeles
    Endocrinology and Metabolic Medicine, Imperial College London, St Mary s Hospital, London, UK
    Eur Heart J 29:2244-51. 2008
    ..The PREDICT Study is a prospective cohort study designed to evaluate coronary artery calcification score (CACS) as a predictor of cardiovascular events in type 2 diabetes (T2DM)...
  76. pmc Prevention and early detection of vascular complications of diabetes
    Sally M Marshall
    Diabetes Research Group, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH
    BMJ 333:475-80. 2006
  77. doi Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
    John D Brunzell
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, and the Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA
    Diabetes Care 31:811-22. 2008
  78. ncbi Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes
    Thoralf Wendt
    Division of Surgical Science, Department of Surgery, Columbia University College of Physicians and Surgeons, 630 West 168th Street, P and S 17 401, New York, NY 10032, USA
    Curr Atheroscler Rep 4:228-37. 2002
    ..Insights into therapeutic strategies to prevent or interrupt these processes are presented...
  79. ncbi Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation
    R G Tilton
    Department of Ophthalmology, Washington University School of Medicine, St Louis, MO 63110
    Diabetes 42:221-32. 1993
    ....
  80. ncbi Cardiovascular risk in women with diabetes
    A A Rivellese
    Department of Clinical and Experimental Medicine, Federico II University of Naples, Napoli, Italy
    Nutr Metab Cardiovasc Dis 20:474-80. 2010
    ..To meet these needs gender specific guidelines and implementation measures may be in order...
  81. pmc Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium
    Hong Ding
    School of Medical Sciences, RMIT University, BundooraWest Campus, Bundoora, Vic, Australia
    Vasc Health Risk Manag 1:55-71. 2005
    ..In addition, we consider the question of biomarkers for vascular disease and evaluate their usefulness for the early detection of and their role as contributors to vascular dysfunction...
  82. pmc Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes
    Gian Paolo Fadini
    Department of Clinical and Experimental Medicine, University of Padova, Medical School, Padova, Italy
    Diabetes Care 33:1097-102. 2010
    ..The present study was designed to describe the extent and potential mechanisms of progenitor cell reduction during the natural history of type 2 diabetes...
  83. ncbi Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment
    Dominick J Angiolillo
    Division of Cardiology, University of Florida, Shands Jacksonville, Jacksonville, Florida 32209, USA
    J Am Coll Cardiol 48:298-304. 2006
    ..This study sought to assess the influence of type 2 diabetes mellitus (T2DM) and the impact of hypoglycemic treatment (insulin vs. noninsulin) on platelet function profiles in patients treated with dual oral antiplatelet therapy...
  84. ncbi A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
    Dominick J Angiolillo
    Division of Cardiology, University of Florida College of Medicine at Shands Jacksonville, Jacksonville, FL 32209, USA
    Eur Heart J 29:2202-11. 2008
    ..The aim of this pilot study was to assess the functional impact of cilostazol in T2DM patients on standard aspirin and clopidogrel treatment...
  85. ncbi Vascular targets of redox signalling in diabetes mellitus
    M M Spitaler
    Department of Medical Biochemistry and Medical Molecular Biology, Karl Franzens University of Graz, Graz, Austria
    Diabetologia 45:476-94. 2002
    ..Thus, a better knowledge of the functional diversity and pathological consequences of each individual pathway activated by ROS id essential to understand the mechanisms of diabetes-associated vascular complications...
  86. ncbi Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging
    P Di Bonito
    Department of Internal Medicine, Cardiology S Maria delle Grazie Pozzuoli Hospital, Naples, Italy
    Diabet Med 22:1720-5. 2005
    ....
  87. ncbi Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes
    E M Dahlén
    Department of Medical and Health Sciences, Linkoping University, Linkoping, Sweden
    Diabet Med 26:384-90. 2009
    ..To explore the association between carotid intima-media thickness (IMT) and the apolipoprotein B (apoB)/apolipoprotein A-I (apoA-I) ratio compared with conventional lipids in middle-aged patients with Type 2 diabetes...
  88. ncbi High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus
    Andreas Pfutzner
    University of Applied Sciences, Rheinbach, Germany
    Diabetes Technol Ther 8:28-36. 2006
    ..Positive results in these trials will further strengthen the value and acceptance of hsCRP, which is recommended as a predictive laboratory marker for cardiovascular disease risk also in patients with diabetes mellitus...
  89. ncbi Costs of lower-extremity ulcers among patients with diabetes
    Karen Stockl
    Prescription Solutions, 3515 Harbor Blvd, M S LC07 264, Costa Mesa, CA 92626, USA
    Diabetes Care 27:2129-34. 2004
    ..The objective of this study was to characterize health care costs associated with diabetic lower-extremity ulcers...
  90. ncbi Molecular targets of diabetic cardiovascular complications
    Fatima K Ahmad
    Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02115, USA
    Curr Drug Targets 6:487-94. 2005
    ..However, clinical studies using these treatments have mainly yielded inconclusive results. The pathogenesis of diabetic vascular complications and results from animal studies and key clinical studies are reviewed here...
  91. pmc Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail
    Daniella Brasacchio
    Epigenetics in Human Health and Disease Laboratory, The Alfred Medical Research and Education Precinct, Baker IDI Heart and Diabetes Institute, Victoria, Australia
    Diabetes 58:1229-36. 2009
    ..We have hypothesized that transient hyperglycemia mediates persistent gene-activating events attributed to changes in epigenetic information...
  92. ncbi Improved endothelial function with metformin in type 2 diabetes mellitus
    K J Mather
    Division of Endocrinology and Metabolism, Indiana University, Indianapolis, USA
    J Am Coll Cardiol 37:1344-50. 2001
    ..This has important implications for the investigation and treatment of vascular disease in patients with type 2 diabetes mellitus...
  93. ncbi Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy
    Sajoscha A Sorrentino
    Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany
    Circulation 121:110-22. 2010
    ..Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL...
  94. ncbi Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia
    Suvi E Heinonen
    Department of Biotechnology and Molecular Medicine, A I Virtanen Institute, University of Kuopio, PO Box 1627, FI 70211, Kuopio, Finland
    Circ Res 101:1058-67. 2007
    ..In conclusion, type 2 diabetic factors induce increased calcification and lesion progression without any lipid changes in a new mouse model of diabetic macroangiopathy...
  95. ncbi Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions
    Andrew M Bakken
    Center for Vascular Disease, Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Vasc Surg 46:946-958; discussion 958. 2007
    ..We examined the consequences of endovascular treatment of the SFA in patients with and without DM...
  96. ncbi Arterial wall structure and dynamics in type 2 diabetes mellitus methodological aspects and pathophysiological findings
    Alejandra I Christen
    Hypertension Section, Metabolic Unit, Universitary Hospital Fundación Favaloro, Buenos Aires, Argentina
    Curr Diabetes Rev 6:367-77. 2010
    ..A complete understanding of the association between arterial alterations and early detection, and type 2 DM, may be critical for the primary prevention of DM-related macro-vascular disease...
  97. ncbi Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events
    Ann Marie Svensson
    Clinical Experimental Research Laboratory, Sahlgrenska University Hospital Ostra, 416 85 Goteborg, Sweden
    Eur Heart J 26:1255-61. 2005
    ....
  98. ncbi The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study
    Joseph DiChiara
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Diabetes 56:3014-9. 2007
    ..Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients...

Research Grants80

  1. Inflammation in obesity: Modulation by Weight Loss
    Paresh Dandona; Fiscal Year: 2009
    ..abstract_text> ..
  2. HYPOXIA INDUCIBLE VEGF PRODUCTION IN SLEEP APNEA
    Andrew Levy; Fiscal Year: 2003
    ....
  3. MACROPHAGE ACTIVATION AND LIPOPROTEIN METABOLISM
    Maria Lopes Virella; Fiscal Year: 2001
    ..Our overall objective is to provide insight into the mechanisms by which anti-LDL antibodies and macrophage activation may contribute to the development(acceleration of the arteriosclerotic process. ..
  4. Defining the Clinical Significance of HbA1c Prior to the Onset of Diabetes
    Elizabeth Selvin; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  5. Retinal Vascular Changes in Type 1 Diabetic African-Americans
    Monique Roy; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  6. Biomarkers in the progression of nephropathy in type 2DM
    Julie Lin; Fiscal Year: 2008
    ..Data on how these modifiable biomarkers are related to kidney function decline could have an important and beneficial impact on treatment and monitoring of nephropathy in type 2 diabetes in the near future. [unreadable] [unreadable]..
  7. African American Study of Kidney Disease and Hypertensi*
    Robert Toto; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  8. Proatherogenic effect of thrombospondins in diabetes
    OLGA STENINA; Fiscal Year: 2005
    ..abstract_text> ..
  9. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2007
    ..Further knowledge of the control of renal glucose release could therefore have therapeutic implications for this disorder and in people with liver and kidney disease. [unreadable] [unreadable]..
  10. RISK FACTORS FOR DIABETIC RETINOPATHY IN BLACK AMERICANS
    Monique Roy; Fiscal Year: 2003
    ..abstract_text> ..
  11. Adjuvant Therapy for Vascular Inflammation in Diabetes
    Sushil Jain; Fiscal Year: 2006
    ..abstract_text> ..
  12. TRAINING CURRICULUM IN PATIENT ORIENTED RESEARCH
    Robert Toto; Fiscal Year: 2004
    ..The proposed program will provide young physicians and scientists with the skills needed to conduct clinical investigations and to compete for federal and non-federal research funding. ..
  13. Ketosis, Vascular Inflammation and Its Therapy in Type 1 Diabetic Patients
    Sushil K Jain; Fiscal Year: 2010
    ..The long-term goal is to understand the role of ketosis in CVD and to discover a relatively low-cost dietary supplement that could be used as an adjuvant therapy for CVD prevention in type 1 diabetes. ..
  14. Regulation of thrombospondin-1 expression by glucose
    Olga I Stenina; Fiscal Year: 2010
    ....
  15. Evaluating reasons for variations in LDL levels
    P Ho; Fiscal Year: 2003
    ..abstract_text> ..
  16. Predictors of Nephropathy in Type 2 Diabetes
    Julie Lin; Fiscal Year: 2008
    ..D., Ph.D., a leading investigator in the field of nutritional epidemiology. This project proposal will provide the foundation for the candidate's future career as an independent and successful clinical scientist in renal research. ..
  17. Functional role of Angiopoietin-2 in diabetic heart
    Jian xiong Chen; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  18. KININS ROLE IN MESANGIAL CELL FIBROSIS
    AYAD JAFFA; Fiscal Year: 2005
    ..abstract_text> ..
  19. Improving Outcomes in Diabetic Nephropathy
    Robert Toto; Fiscal Year: 2008
    ..PERFORMANCE SITE ========================================Section End=========================================== ..
  20. ORGANIZATIONAL CHARACTERISTICS AND CHRONIC DISEASE CARE
    PATRICK O CONNOR; Fiscal Year: 2001
    ..Results will be relevant to policy makers, purchasers, health plans, medical groups, and clinics that are seeking to improve chronic disease care, and may suggest new intervention strategies worth further investigation. ..
  21. AGEs and cardiovascular disease in type 1 diabetes
    Mark E Cooper; Fiscal Year: 2010
    ..It is anticipated that these studies will ultimately lead to better strategies to treat and prevent diabetic vascular complications. ..
  22. Role of Erythrocytes in Circulatory Control
    Randy Sprague; Fiscal Year: 2004
    ..abstract_text> ..
  23. Mechanisms of ATP Release from RBC's
    Randy Sprague; Fiscal Year: 2007
    ..abstract_text> ..
  24. Molecular genetics of glucose homeostasis and fat
    Donald Bowden; Fiscal Year: 2009
    ..g. create an "ultra high density" SNP map of the associated chromosomal region. These new SNPs will be genotyped on the IRASFS DNAs to identify the trait defining alleles. ..
  25. Comparative Effectiveness of Comprehensive Care for Adults with SMI
    TODD PATRICK GILMER; Fiscal Year: 2010
    ....
  26. Modifying obesogenic homes: Impact on weight maintenance
    Amy Gorin; Fiscal Year: 2007
    ..This home environmental approach, if successful, has potential applications to the maintenance of other important health behaviors. [unreadable] [unreadable]..
  27. PREMIER Maintenance Trial(MAINTENANCE)
    Laura Svetkey; Fiscal Year: 2007
    ..The purpose of this proposal is to develop and test two such interventions, which, if effective, should complement ongoing efforts to stem the obesity epidemic and ultimately prevent obesity-related CVD. ..
  28. Comparative effectiveness of diabetes prevention strategies in women with GDM
    Assiamira Ferrara; Fiscal Year: 2010
    ..Finding that this intervention is cost-effective in this setting should motivate its adoption at KP as well as in other health care systems. ..
  29. Lipolytic Mechanisms of PPAR Activation
    Jorge Plutzky; Fiscal Year: 2007
    ..Through these programmatic efforts, insight will be gained into lipolysis as a mechanism for selective endogenous PPAR activation, and its distal transcriptional effects. ..
  30. Macrophage Cholesterol Metabolism and ApoE Synthesis
    Theodore Mazzone; Fiscal Year: 2007
    ..abstract_text> ..
  31. Development of a tool to measure food availability in the home
    June Stevens; Fiscal Year: 2007
    ..By accurately measuring what foods are in the home, we can learn how food availability influences diet. [unreadable] [unreadable] [unreadable]..
  32. Neurohormonal Blockade and Outcomes in Diastolic Heart Failure
    Ali Ahmed; Fiscal Year: 2010
    ..The proposed study will examine the effect of neurohormonal blockade in propensity matched OPTIMIZE-HF participants with diastolic heart failure. ..
  33. Egr-1, PKC Beta, Signalling and Atherosclerosis
    Shi Fang Yan; Fiscal Year: 2009
    ....
  34. Beta Cell Adaptation to Stress in Baboon Pancreas After Partial Pancreatectomy
    FRANCO BATTISTA FOLLI; Fiscal Year: 2010
    ....
  35. MIND-BODY-BEHAVIORAL MED CLINICAL TRIALS INFRASTRUCTURE
    Karina Davidson; Fiscal Year: 2008
    ..The ultimate goal will be to make our findings available to 3 target audiences: 1) the network of investigators at Columbia; 2) the behavioral medicine community; and 3) the general medical community. ..
  36. Vascular risk after kidney transplantation
    Jennifer L Larsen; Fiscal Year: 2010
    ..The study will also provide preliminary evidence for the efficacy of Vitamin D and omega 3 fatty acid supplementation in modifying traditional and nontraditional CVD risk factors as well as CVD progression after KTX. ..
  37. GENE/DIET EFFECTS ON PLASMA LIPOPROTEIN LEVELS
    Jose M Ordovas; Fiscal Year: 2010
    ..This evidence-based knowledge will contribute to a rational approach toward more effective dietary recommendations aimed to decrease health disparities and to a better CVD prevention. ..
  38. Inflammation and Injury in Obesity Hypertension in African American Adolescents
    Bonita Falkner; Fiscal Year: 2010
    ..abstract_text> ..
  39. Inflammation & Prognosis in Decompensated Heart Failure
    GARY FELKER; Fiscal Year: 2008
    ..Felker's development into an established independent clinical investigator with expertise in both complex clinical research methodology and the role of inflammation in the pathophysiology of heart failure. ..
  40. Hypertension Improvement Project (HIP)
    Laura Svetkey; Fiscal Year: 2008
    ..3 for the primary outcome. The HIP study will test practical interventions for improving hypertension control that can be broadly implemented and reduce CVD risk. ..
  41. Adipocyte Lipid Metabolism and ApoE Expression
    Theodore Mazzone; Fiscal Year: 2009
    ..For these studies, adipose tissue will be collected from the gluteal and abdominal subcutaneous regions, and from the intraperitoneal visceral region, of patients undergoing bariatric surgery;and utilized for isolation of adipocytes. ..
  42. Enhancing Exercise Participation in Overweight Women
    John Jakicic; Fiscal Year: 2006
    ..It is believed that this proposed study will lead to improvements in exercise participation in overweight women, which will result in improvements in the long-term treatment of obesity. ..
  43. GENETIC ANALYSIS OF HUMAN HYPERTENSIVE ESRD
    Barry Freedman; Fiscal Year: 2001
    ..The identification of hypertension-associated renal failure genes would form a genetic basis for detection of high risk individuals and development of intervention and treatment strategies for prevention of H-ESRD. ..
  44. Leptin and insulin action in the brain; role in obesity
    Kevin Niswender; Fiscal Year: 2007
    ..These aims also provide the background and training necessary for the development of an independent research program and will be conducted in the context of rich training environment ..
  45. IMPAIRED CORONARY ARTERY FUNCTION IN INSULIN RESISTANCE
    David Busija; Fiscal Year: 2003
    ..Findings from this project may provide important information that can be used in future studies to design treatments to prevent or abort the cardiovascular complications of insulin resistance. ..
  46. Obesity in early and middle adulthood and retirement
    June Stevens; Fiscal Year: 2004
    ..support researchers interested in undertaking secondary data analyses of data related to ... behavioral research on aging" and "... determinants of retirement .... " ..
  47. COLLAGEN CROSSLINKING BY THE MAILLARD REACTIOIN IN AGING
    Vincent Monnier; Fiscal Year: 2004
    ..Our approach, we expect, will result in the first comprehensive, hierarchical map of collagen crosslinks that for, during aging. ..
  48. EFFECT OF DIABETES AND HYPERTENSION ON ISCHEMIC INJURY
    Stephen Schaffer; Fiscal Year: 2003
    ..Cell culture studies will be complimented by studies using an isolated heart model to test the hypothesis that hypertensive diabetic hearts will be more susceptible to an ischemic insole because of elevated levels of angiotensin. ..
  49. Cerebrovascular Dysfunction in Insulin Resistance
    David Busija; Fiscal Year: 2004
    ..We believe that our studies will result in new and important findings that will lead to improved therapies to reduce morbidity and mortality in IR individuals. ..
  50. CORTISOL, CENTRAL OBESITY, AND INSULIN RESISTANCE
    Jonathan Purnell; Fiscal Year: 2003
    ....
  51. Endogenous Mechanisms of PPAR Modulation
    Jorge Plutzky; Fiscal Year: 2005
    ..Together, these studies integrate biochemical, biologic, and in vivo models to better understand how endogenous modulation of PPAR activity may determine biologic responses. ..
  52. A MENTOR-BASED APPROACH TO LONG-TERM WEIGHT LOSS
    John Jakicic; Fiscal Year: 2001
    ..It is believed that a mentor- based intervention will lead to improvements in the long-term treatment of obesity. ..
  53. Brain insulin and leptin resistance in obesity
    Kevin Niswender; Fiscal Year: 2008
    ..Aim 4: To determine if genetic enhancement of the hypothalamic PI3K pathway enhances insulin and leptin sensitivity and attenuates DIO. ..
  54. CAROTENOID BINDING PROTEIN AND CAROTENOID METABOLISM
    Raj Lakshman; Fiscal Year: 2002
    ..2. Molecular biology techniques to measure CCBP mRNA levels in different tissues and to clone its cDNA. 3. HPLC procedures for quantification of various carotenoids and retinoids. ..
  55. HRQL Impact of Chronic Conditions and Comorbidity Burden
    Patrick Sullivan; Fiscal Year: 2006
    ..S. [unreadable] [unreadable]..
  56. KALLIKREINS-KININS AND DIABETIC VASCULAR COMPLICATIONS
    AYAD JAFFA; Fiscal Year: 2002
    ..abstract_text> ..
  57. STUDY OF OSTEOPOROTIC FRACTURES
    Teresa Hillier; Fiscal Year: 2005
    ....
  58. Androgens and Cardiovascular Risk in African Americans
    Bonita Falkner; Fiscal Year: 2005
    ..The results of this project can contribute to the development of prevention and earlier intervention strategies, including more specific therapeutic targets, for this high-risk minority population. ..
  59. MECHANISMS OF ENDOTHELIAL DYSFUNCTION IN DIABETICS
    Joshua Beckman; Fiscal Year: 2003
    ..abstract_text> ..
  60. ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2
    Mark Hlatky; Fiscal Year: 2006
    ..The investigators further expect that this collaborative effort will translate into a new practical clinical paradigm that will be used for treatment of Type II diabetic patients. ..
  61. Collaborative Clinical Culture and Quality of Care
    Sheldon Greenfield; Fiscal Year: 2003
    ..The results of this study will provide insight into whether HCTs are associated with high staff morale and high quality of care. ..
  62. PHYSICIAN INTERVENTION TO IMPROVE DIABETES CARE
    PATRICK O CONNOR; Fiscal Year: 2002
    ..The study will have substantial impact on clinical practice and policy whether the results are positive or negative. If successful, the interventions will be easily disseminated to other primary care practice settings. ..
  63. Poly(ADP-ribose) synthetase inhibition and diabetes
    Csaba Szabo; Fiscal Year: 2004
    ....
  64. PARS and peroxynitrite induced cell death
    Csaba Szabo; Fiscal Year: 2009
    ..4 To establish the role of Bel family proteins in the regulation of calcium homeostasis during peroxynitrite-induced cell death. The studies proposed here have broad pathophysiological relevance. ..
  65. Mechanisms of Pro-Thrombosis in Diabetes Mellitus
    David Schneider; Fiscal Year: 2003
    ..Further, these results will define the importance of prothrombotic potential in diabetic subjects while potentially identifying new therapeutic targets in patients with diabetes and other insulin resistant states. ..
  66. C-Reactive Protein and Exercise in Postmenopausal Women
    Timothy Church; Fiscal Year: 2003
    ..These studies represent an innovative, unique, timely, and cost-effective opportunity to quickly explore the relation between CRP, physical activity, and HRT. ..
  67. RAGE and a Novel Tumor Axis
    Ann Schmidt; Fiscal Year: 2005
    ....
  68. Effect of Exercise on Prevention of Weight Gain
    John Jakicic; Fiscal Year: 2006
    ..The results of this study will have a significant impact on exercise recommendations for preventing weight gain in adults. ..
  69. Reducing Clinical Inertia in Diabetes Care
    PATRICK O CONNOR; Fiscal Year: 2007
    ..Results of this project will have significant clinical and policy implications. ..
  70. Poly(ADP-ribose)and diabetic erectile dysfunction
    FANGMING ZUO; Fiscal Year: 2004
    ..If these studies confirm that Inotek's PARP inhibitor is effective in improving erectile function in diabetes, a Phase II component will be triggered, which will focus on formal preclinical safety testing. ..
  71. Autonomic Function in Insulin Resistance and Diabetes
    Mercedes Carnethon; Fiscal Year: 2005
    ..abstract_text> ..
  72. Myicardial injury: role of poly (ADP-ribose) synthetase
    Csaba Szabo; Fiscal Year: 2005
    ..Further, based on exciting preliminary data, the final, fifth aim is focusing in establishing the role of PARS in myocardial preconditioning. ..
  73. DOSE-RESPONSE OF EXERCISE ON LONG-TERM WEIGHT LOSS
    John Jakicic; Fiscal Year: 2002
    ..The investigators believe that the proposed study will lead to improvements in the long-term treatment of obesity. ..
  74. Novel preservation fluid for organ transplantation
    Jon Mabley; Fiscal Year: 2003
    ..abstract_text> ..
  75. Adenosine-3 agonists for the suppression of arthritis
    Csaba Szabo; Fiscal Year: 2003
    ..A novel A3 receptor agonist may represent a useful anti-inflammatory adjunct to current therapeutic regimens; funding of the current SBIR Phase II will allow for starting human safety trials in 2 years. ..
  76. PARS INHIBITOR FOR THE THERAPY OF CIRCULATORY SHOCK
    Ludmila Belayev; Fiscal Year: 2003
    ..The current project will enable the applicants to move forward in two years, near to the level of the beginning of Phase II efficacy trial in septic patients. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  77. Poly(ADP-ribose)Polymerase & Doxorubicin Cardiotoxicity
    Jon Mabley; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATIONS: The annual anticipated revenues for an effective therapeutic to prevent anti-cancer-drug induced cardiodepression is over $100 million in the US alone. ..
  78. Mechanisms of cardiovascular dysfunction in diabetes
    Csaba Szabo; Fiscal Year: 2005
    ..The final aim of the study is to investigate the activation of PARP in human microvasculature, and to correlate the degree of PARP activation with the degree of endothelial dysfunction in humans. ..